$4.15
-0.02-0.60%
At close: -
$4.05
-0.10-2.41%
After Hours: May 12, 9:00 AM EDT
Comments
Loading...
Radiopharm Theranostics Analyst Ratings and Price Targets | NASDAQ:RADX | Benzinga
Radiopharm Theranostics Ltd has a consensus price target of $13.5 based on the ratings of 2 analysts. The high is $15 issued by B. Riley Securities on March 12, 2025. The low is $12 issued by Maxim Group on May 1, 2025. The 2 most-recent analyst ratings were released by Maxim Group and B. Riley Securities on May 1, 2025 and March 12, 2025, respectively. With an average price target of $13.5 between Maxim Group and B. Riley Securities, there's an implied 233.33% upside for Radiopharm Theranostics Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Maxim Group
B. Riley Securities
1calculated from analyst ratings
Analyst Ratings for Radiopharm Theranostics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/01/2025 | Buy Now | 196.3% | Maxim Group | Michael Okunewitch27% | → $12 | Initiates | → Buy | Get Alert |
| 03/12/2025 | Buy Now | 270.37% | B. Riley Securities | Yuan Zhi29% | → $15 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Radiopharm Theranostics (RADX) stock?
The latest price target for Radiopharm Theranostics (NASDAQ:RADX) was reported by Maxim Group on May 1, 2025. The analyst firm set a price target for $12.00 expecting RADX to rise to within 12 months (a possible 196.30% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Radiopharm Theranostics (RADX)?
The latest analyst rating for Radiopharm Theranostics (NASDAQ:RADX) was provided by Maxim Group, and Radiopharm Theranostics initiated their buy rating.
When was the last upgrade for Radiopharm Theranostics (RADX)?
There is no last upgrade for Radiopharm Theranostics
When was the last downgrade for Radiopharm Theranostics (RADX)?
There is no last downgrade for Radiopharm Theranostics.
When is the next analyst rating going to be posted or updated for Radiopharm Theranostics (RADX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Radiopharm Theranostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Radiopharm Theranostics was filed on May 1, 2025 so you should expect the next rating to be made available sometime around May 1, 2026.
Is the Analyst Rating Radiopharm Theranostics (RADX) correct?
While ratings are subjective and will change, the latest Radiopharm Theranostics (RADX) rating was a initiated with a price target of $0.00 to $12.00. The current price Radiopharm Theranostics (RADX) is trading at is $4.05, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
